Ever after.

Happily is not how patients fared after everolimus in RTOG 0913. This phase 2 trial randomized patients with newly diagnosed glioblastoma to standard radiation with temozolomide +/- everolimus. Patients in the everolimus arm suffered significantly higher rates of grade 4 lymphopenia and thrombocytopenia as well as treatment-related deaths, all translating to a significantly worse overall survival (by 5 months) than with standard therapy. | Chinnaiyan, Neuro Oncol 2018